Jiaoli Wang1,2†
Haoran Hu3†
Haixia Du4Man Luo2Yilan Cao3
Jiaping Xu3Tianhang Chen4Yilei Guo3Qixiang Li3Wen Chen3Yifei Zhang5Jin Han3*
Haitong Wan1,4*by Wang J, Hu H, Du H, Luo M, Cao Y, Xu J, Chen T, Guo Y, Li Q, Chen W, Zhang Y, Han J and Wan H (2022). Front. Pharmacol. 13:852604. doi: 10.3389/fphar.2022.852604
In the published article, there was an error in affiliations 1, 2, 3 and 4.
Instead of “Jiaoli Wang1, Haoran Hu2, Haixia Du3, Man Luo1, Yilan Cao2, Jiaping Xu1, Tianhang Chen3, Yilei Guo2, Qixiang Li2, Wen Chen1, Yifei Zhang5, Jin Han3* and Haitong Wan4*
1Department of Respiratory Medicine, Hangzhou First People’s Hospital, Hangzhou, China, 2College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China, 3College of Life Science, Zhejiang Chinese Medical University, Hangzhou, China, 4Zhejiang Chinese Medical University, Hangzhou, China, 5Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.”
It should be “Jiaoli Wang1,2†, Haoran Hu3†, Haixia Du4, Man Luo2, Yilan Cao3, Jiaping Xu3, Tianhang Chen4, Yilei Guo3, Qixiang Li3, Wen Chen3, Yifei Zhang5, Jin Han3* and Haitong Wan1,4*
1Zhejiang Chinese Medical University, Hangzhou, China, 2Department of Respiratory Medicine, Hangzhou First People’s Hospital, Hangzhou, China, 3College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China, 4College of Life Science, Zhejiang Chinese Medical University, Hangzhou, China, 5Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
†These authors have contributed equally to this work.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: Yinhuapinggan (YHPG), traditional Chinese medicine (TCM), community-acquired drug-resistant bacterial pneumonia (CDBP), multidrug resistance, clinical trial, clinical efficacy
Citation: Wang J, Hu H, Du H, Luo M, Cao Y, Xu J, Chen T, Guo Y, Li Q, Chen W, Zhang Y, Han J and Wan H (2022) Corrigendum: Clinical efficacy protocol of yinhuapinggan granules: A randomized, double-blind, parallel, and controlled clinical trial program for the intervention of community-acquired drug-resistant bacterial pneumonia as a complementary therapy. Front. Pharmacol. 13:986640. doi: 10.3389/fphar.2022.986640
Received: 05 July 2022; Accepted: 06 July 2022;
Published: 16 August 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Wang, Hu, Du, Luo, Cao, Xu, Chen, Guo, Li, Chen, Zhang, Han and Wan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jin Han, 3232168@163.com; Haitong Wan, whtong@126.com
†These authors have contributed equally to this work
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.